Panagora Asset Management Inc Theravance Biopharma, Inc. Transaction History

Panagora Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.41 - $10.34 $1.41 Million - $1.73 Million	-167,642 Reduced 61.93%	103,049 $934,000
Q1 2022 May 12, 2022	BUY	$8.33 - $12.96 $94,095 - $146,396	11,296 Added 4.35%	270,691 $2.59 Million
Q4 2021 Feb 10, 2022	BUY	$7.42 - $11.05 $621,209 - $925,117	83,721 Added 47.66%	259,395 $2.87 Million
Q3 2021 Nov 10, 2021	SELL	$6.77 - $14.41 $23,871 - $50,809	-3,526 Reduced 1.97%	175,674 $1.3 Million
Q2 2021 Aug 11, 2021	SELL	$14.52 - $22.46 $114,925 - $177,770	-7,915 Reduced 4.23%	179,200 $2.6 Million
Q1 2021 May 12, 2021	BUY	$16.57 - $21.08 $35,260 - $44,858	2,128 Added 1.15%	187,115 $3.82 Million
Q4 2020 Feb 10, 2021	BUY	$14.89 - $20.16 $1.34 Million - $1.81 Million	90,026 Added 94.8%	184,987 $3.29 Million
Q3 2020 Nov 13, 2020	BUY	$14.79 - $22.49 $1,567 - $2,383	106 Added 0.11%	94,961 $1.4 Million
Q2 2020 Aug 12, 2020	BUY	$20.64 - $30.69 $1.96 Million - $2.91 Million	94,855 New	94,855 $1.99 Million
Q2 2019 Aug 09, 2019	SELL	$15.6 - $25.15 $48,531 - $78,241	-3,111 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$23.88 - $34.96 $74,290 - $108,760	3,111	3,111 $107,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.